Published in Clin Infect Dis on February 01, 2010
Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis (2011) 2.86
Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis (2010) 1.58
Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort. AIDS Res Ther (2011) 1.11
HIV outcomes in Hepatitis B virus coinfected individuals on HAART. J Acquir Immune Defic Syndr (2014) 0.92
Hepatitis B vaccine antibody response and the risk of clinical AIDS or death. PLoS One (2012) 0.91
Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort. World J Gastroenterol (2013) 0.87
Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy. J Viral Hepat (2013) 0.83
The Role of Sexually Transmitted Infections in HIV-1 Progression: A Comprehensive Review of the Literature. J Sex Transm Dis (2013) 0.83
Incident Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Men Who Have Sex With Men From Pre-HAART to HAART Periods: A Cohort Study. Ann Intern Med (2015) 0.83
The timing of hepatitis B virus (HBV) immunization relative to human immunodeficiency virus (HIV) diagnosis and the risk of HBV infection following HIV diagnosis. Am J Epidemiol (2010) 0.82
Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients. ISRN Gastroenterol (2011) 0.81
Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study. Virol J (2013) 0.76
Prevalence of Post-Treatment Controller Phenotype is Rare in HIV-infected Persons after Stopping Antiretroviral Therapy. J Acquir Immune Defic Syndr (2017) 0.75
Insights into human immunodeficiency virus-hepatitis B virus co-infection in India. World J Virol (2015) 0.75
Lower Baseline Germinal Center Activity and Preserved Th1 Immunity Are Associated With Hepatitis B Vaccine Response in Treated HIV Infection. Pathog Immun (2017) 0.75
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep (1992) 22.29
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS (2005) 4.40
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS (2000) 2.14
Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer (2005) 2.09
Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis (2002) 2.06
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis (2008) 2.06
Behavioral counseling to prevent sexually transmitted infections: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med (2008) 1.89
Surveillance for acute viral hepatitis--United States, 2006. MMWR Surveill Summ (2008) 1.86
Epidemiology of hepatitis B in the United States. Hepatology (2009) 1.81
Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS (2010) 1.80
Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis (2003) 1.80
Natural history of chronic hepatitis B in co-infected patients. J Hepatol (2005) 1.77
Increasing age at HIV seroconversion from 18 to 40 years is associated with favorable virologic and immunologic responses to HAART. J Acquir Immune Defic Syndr (2008) 1.66
Prevention with HIV-seropositive men who have sex with men: lessons from the Seropositive Urban Men's Study (SUMS) and the Seropositive Urban Men's Intervention Trial (SUMIT). J Acquir Immune Defic Syndr (2004) 1.65
Incidence of acute hepatitis B--United States, 1990-2002. MMWR Morb Mortal Wkly Rep (2004) 1.54
Trends in primary and secondary syphilis among men who have sex with men in the United States. Am J Public Health (2007) 1.47
Management of hepatic complications in HIV-infected persons. J Infect Dis (2008) 1.42
Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS (2008) 1.40
Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS (2003) 1.34
Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis (2007) 1.25
Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol (1997) 1.24
Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study. J Med Assoc Thai (2004) 1.07
[Ambulatorial prevalence of hepatitis B and C markers in patients with human immunodeficiency virus infection in a general hospital]. Arq Gastroenterol (2006) 1.05
Association between syphilis, antibodies to herpes simplex virus type 2, and recreational drug use and hepatitis B virus infection in the Women's Interagency HIV Study. Clin Infect Dis (2004) 0.92
Seroprevalence and risk factors of hepatitis B, hepatitis C, and human cytomegalovirus among HIV-infected and high-risk uninfected adolescents: findings of the REACH Study. Adolescent Medicine HIV/AIDS Research Network. Sex Transm Dis (2000) 0.82
The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science (2005) 17.00
Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr (2006) 5.87
Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe (2008) 4.55
Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis (2009) 4.48
Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med (2003) 4.27
Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS (2009) 4.02
Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis (2009) 3.48
CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol (2007) 3.31
CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med (2008) 2.94
Host determinants of HIV-1 control in African Americans. J Infect Dis (2010) 2.90
Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis (2011) 2.88
Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis (2011) 2.86
Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation (2010) 2.59
Is HIV becoming more virulent? Initial CD4 cell counts among HIV seroconverters during the course of the HIV epidemic: 1985-2007. Clin Infect Dis (2009) 2.50
Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proc Natl Acad Sci U S A (2008) 2.38
Broad-spectrum respiratory tract pathogen identification using resequencing DNA microarrays. Genome Res (2006) 2.11
Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer (2005) 2.09
Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS (2008) 2.02
Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS (2010) 1.80
Natural history of colonization with gram-negative multidrug-resistant organisms among hospitalized patients. Infect Control Hosp Epidemiol (2010) 1.80
Infection-associated clinical outcomes in hospitalized medical evacuees after traumatic injury: trauma infectious disease outcome study. J Trauma (2011) 1.77
Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One (2010) 1.75
CCL3L1 and HIV/AIDS susceptibility. Nat Med (2009) 1.73
Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr (2009) 1.70
HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles. PLoS One (2008) 1.69
Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDS (2008) 1.69
Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy. J Clin Microbiol (2003) 1.66
Increasing age at HIV seroconversion from 18 to 40 years is associated with favorable virologic and immunologic responses to HAART. J Acquir Immune Defic Syndr (2008) 1.66
Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res Ther (2010) 1.63
Chlorhexidine-impregnated cloths to prevent skin and soft-tissue infection in Marine recruits: a cluster-randomized, double-blind, controlled effectiveness trial. Infect Control Hosp Epidemiol (2010) 1.60
Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS (2006) 1.55
Invasive mold infections following combat-related injuries. Clin Infect Dis (2012) 1.55
Melioidosis after brief exposure: a serologic survey in US Marines. Am J Trop Med Hyg (2009) 1.55
Immunologic and virologic events in early HIV infection predict subsequent rate of progression. J Infect Dis (2010) 1.53
Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis (2010) 1.52
The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry. Blood (2009) 1.51
Early immunologic correlates of HIV protection can be identified from computational analysis of complex multivariate T-cell flow cytometry assays. Bioinformatics (2012) 1.46
High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis (2010) 1.46
Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: what is the impact of CD4 counts and HAART use? J Acquir Immune Defic Syndr (2010) 1.46
Untreated HIV infection and large and small artery elasticity. J Acquir Immune Defic Syndr (2009) 1.41
Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS (2010) 1.39
Caspase-11 activation in response to bacterial secretion systems that access the host cytosol. PLoS Pathog (2013) 1.38
Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials (2008) 1.32
Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS. PLoS One (2011) 1.29
Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial. J Infect Dis (2012) 1.25
The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naïve participants started on three different antiretroviral therapy strategies. HIV Clin Trials (2007) 1.21
Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. AIDS (2014) 1.19
CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy. Clin Infect Dis (2010) 1.18
Safety of the pandemic H1N1 influenza vaccine among pregnant U.S. military women and their newborns. Obstet Gynecol (2013) 1.18
Role of CCL3L1-CCR5 genotypes in the epidemic spread of HIV-1 and evaluation of vaccine efficacy. PLoS One (2008) 1.15
Impact of depression on HIV outcomes in the HAART era. J Antimicrob Chemother (2008) 1.14
Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. Hum Mol Genet (2012) 1.14
Multidrug-resistant gram-negative bacteria colonization of healthy US military personnel in the US and Afghanistan. BMC Infect Dis (2013) 1.14
Obesity among HIV-infected persons: impact of weight on CD4 cell count. AIDS (2010) 1.14
Ileitis: when it is not Crohn's disease. Curr Gastroenterol Rep (2010) 1.12
Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine (2009) 1.11